Abstract:Objective To explore the effects of dialysate calcium concentrations (DCC)on risks of adverse reactions occurred in maintenance hemodialysis patients during dialysis. Methods The subjects were end-stage renal disease (ESRD)patients in stable condition who were treated with maintenance dialysis in the First Affiliated Hospital,Zhejiang University from June to October 2016. According to the DCC,the patients were randomly divided into 3 groups,the 1.25 mmol/L group,the 1.35 mmol/L group,and the 1.50 mmol/L group;the observation time was 12 weeks. The urea clearance index Kt/V,urea reduction rate (URR),mean arterial pressure before and after dialysis,the serum calcium,serum phosphorus,intact parathyroid hormone (iPTH),and alkaline phosphatase (ALP)levels before and after dialysis,and the incidence of muscle spasm,nausea and vomiting,headache,chest tightness,and arrhythmia in hemodialysis patients in the 3 groups were compared. Results A total of 273 patients entered the study,including 159 males and 114 females with ages from 25 to 83 years and average age of (52 ± 9)years. Each of the 1.25 mmol/L,1.35 mmol/L,and 1. 50 mmol/L groups comprised 91 patients. The differences of baseline data in patients in the 3 groups were not statistically significant (P＞0.05). After 12 weeks of hemodialysis,the differences of Kt/V and URR in patients in the 3 groups were not statistically significant (all P＞0.05);the differences of the mean arterial pressures in patients in the 1.25 and 1.35 mmol/L groups [(102 ± 9)and (103 ±11)mmHg,respectively]were not statistically significant (all P ＞0.0.5);the mean arterial pressure in the patients in the 1.50 mmol/L group was higher than that before hemodialysis [(120 ± 12) mmHg vs.(103 ± 9)mmHg,P＜0.01]and was higher markedly than that in 1.25 and 1.35 mmol/L groups (all P＜0.01);the serum calcium level in patients in the 1.25 mmol/L group was lower than that before hemodialysis [(1.94 ± 0.31)mmol/L vs.(2.24 ± 0.18)mmol/L,P＜0.01];the serum calcium level in the patients in the 1.50 mmol/L group was higher than that before hemodialysis [(2.54 ± 0.18) mmol/L vs.(2.24 ± 0.17)mmol/L,P＜0.01];the iPTH and ALP levels in patients in the 1.25 mmol/L group were higher than those before hemodialysis [(356 ± 68)U vs.(291 ± 49)U,(443 ± 45)U vs. (343 ± 58)U,all P ＜0.01]. During dialysis,the incidence of muscle spasm in patients in the 1.25 mmol/L group was higher than that in the 1.35 mmol/L and 1.50 mmol/L groups [14.28% (13/91)vs. 5.49% (5/91)and 4.39% (4/91),all P ＜0.05];the incidence of headache in patients in the 1.50 mmol/L group was higher than that in the 1.25 mmol/L and 1.35 mmol/L groups [14.28% (13/91)vs. 3.30% (3/91)and 5.49% (5/91),P ＝0.01 and P ＜0.05]. The differences in incidences of chest tightness,arrhythmia,nausea and vomiting were not statistically significant (all P＞0.05). Conclusion The dialysate with calcium concentration of 1.35 mmol/L may reduce the incidence of muscle spasm,does not increase the incidence of hypertension and headache,and effectively reduce the risk of adverse reactions in maintenance hemodialysis patients,while ensuring the adequacy of dialysis.

The Differences Of Asymmetric Dimethylarginine Removal By Different Dialysis Treatments

Removal of Asymmetric Dimethylarginine by Different Dialysis Methods in Uremia Patients

Effect of Super-Flux Polyethersulfone Dialysis Membrane on the Removal of Asymmetrical Dimethylarginine:A Pilot Clinical Study

Clinical Trail on Asymmetric Dimethylarginineclearance by Hemodialysis and Its Correlation with Nitric Oxide Production

Comparative Analysis of Efficacy and Prognosis of Hemodialysis and Peritoneal Dialysis for End-Stage Renal Disease: A Meta-analysis.

Asymmetric dimethylarginine serum concentration in normal weight and obese CKD patients treated with hemodialysis

The solutes removal capability in four different membrane dialyzers in hemodialysis maintenance patients

Elevation of serum apelin-13 is positively correlated with ADMA in patients on maintenance hemodialysis.

Relations Between Plasma Asymmetric Dimethylarginine (adma) and Risk Factors for Coronary Disease

Serum and Tissue Levels of Advanced Glycation End Products and Risk of Mortality in Patients on Maintenance Hemodialysis

Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients

The Associations of Uric Acid, Cardiovascular and All-Cause Mortality in Peritoneal Dialysis Patients.

The Significance of Follow-Up Serum Uric Acid Levels in Predicting All-Cause Mortality and Cardiovascular Mortality in Peritoneal Dialysis Patients.

Removal of uremic retention products by hemodialysis is coupled with indiscriminate loss of vital metabolites

Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of l-arginine on its metabolism

A Study on Adrenomedullin Level in Patients with Chronic Renal Failure and Its Changes during Dialysis

Randomized Controlled Trial of Dialysate Calcium Concentrations on Risks of Adverse Reactions in Hemodialysis Patients During Dialysis

Early Mortality and Risk Analysis in Adult Patients with Maintenance Hemodialysis

Accumulation of Circulating Advanced Oxidation Protein Products is an Independent Risk Factor for Ischaemic Heart Disease in Maintenance Haemodialysis Patients

A study of plasma Adiponectin levels and related factors in maintenance hemodialysis and peritoneal dialysis patients

Asymmetric dimethylarginine and whole blood viscosity in renal failure